[{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AD-227A","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AD-214","moa":"||CXCR4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AD-214","moa":"||CXCR4 receptor","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"||Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lansoprazole","moa":"||Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-214-02","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-213-B","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD-213-B","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AD-221","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-2281","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-227","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-2284","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-1151","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AD-120","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PA-111","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AD-223","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD-2081","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD-221","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AD-218","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AD-224","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AD-209","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AD-2021","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AD-2281","moa":"||PARP-1\/2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD209","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AD-209","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AD-2072","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-208","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-2111","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"},{"orgOrder":0,"company":"AddPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AD-104-A","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by AddPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 17, 2025

                          Lead Product(s) : PA-111,PA-111A

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 08, 2025

                          Lead Product(s) : AD-120A,AD-120

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 30, 2025

                          Lead Product(s) : AD-115A,AD-1151

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 19, 2025

                          Lead Product(s) : AD-227A,AD-227B,AD-227

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 19, 2025

                          Lead Product(s) : AD-228B,AD-2284

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 05, 2025

                          Lead Product(s) : AD-228A,AD-2281,AD-2282

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 24, 2024

                          Lead Product(s) : AD-2281,AD-2282

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 07, 2024

                          Lead Product(s) : AD-2021,AD-2022

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 04, 2024

                          Lead Product(s) : AD-227A,AD-227B

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 04, 2024

                          Lead Product(s) : AD-209,Inapplicable

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank